Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1984 Dec;81(24):7927–7931. doi: 10.1073/pnas.81.24.7927

Transplantation of human or rodent tumors into cyclosporine-treated mice: a feasible model for studies of tumor biology and chemotherapy.

H J Fingert, A Treiman, A B Pardee
PMCID: PMC392266  PMID: 6595666

Abstract

Total growth of transplanted human or rodent tumors in the subrenal capsule of mice was much improved by treatment with cyclosporine (CSA, cyclosporin A). Tumor size increased rapidly between days 6 and 12 after implantation, CSA injected on days 1-5 or 2-8 prevented tumor regression. In contrast, immunologic regression occurred after 6 days in absence of the drug. Tumor growth was comparable in CSA-treated mice, athymic nude mice with human tumors, or normal mice with syngeneic rodent tumors. Studies with rodent tumors in syngeneic mice showed that the CSA treatments had no antitumor effect. Inflammatory infiltration was seen on days 6-12 after tumor implantation into control mice. Immunoperoxidase staining showed murine T cells to be prominent in the infiltrate. In contrast, tumors in CSA-treated mice contained minimal inflammatory infiltrate even 12 days after implantation. Allogeneic tumors in CSA-treated mice caused neovascularization, metastases, and local invasion into the kidney. cis-Diamminedichloroplatinum showed highly significant activity against human tumors in CSA-treated mice during the period 6-10 days after tumor implantation but showed no statistically significant antitumor activity 0-6 days after implantation in mice not treated with CSA. We suggest that in CSA-treated mice the subrenal capsule assay for tumor growth provides a rapid, economical model for investigations in vivo of mouse or human tumor biology, for drug screening with a standard tumor, or for determination of optimal treatment of particular human tumors.

Full text

PDF
7927

Images in this article

7929Image
on p.7929
7929Image
on p.7929
7930Image
on p.7930
7930Image
on p.7930
7930Image
on p.7930

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bhan A. K., DesMarais C. L. Immunohistologic characterization of major histocompatibility antigens and inflammatory cellular infiltrate in human breast cancer. J Natl Cancer Inst. 1983 Sep;71(3):507–516. [PubMed] [Google Scholar]
  2. Bogden A. E., Cobb W. R., Lepage D. J., Haskell P. M., Gulkin T. A., Ward A., Kelton D. E., Esber H. J. Chemotherapy responsiveness of human tumors as first transplant generation xenografts in the normal mouse: six-day subrenal capsule assay. Cancer. 1981 Jul 1;48(1):10–20. doi: 10.1002/1097-0142(19810701)48:1<10::aid-cncr2820480105>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  3. Bogden A. E., Von Hoff D. D. Comparison of the human tumor cloning and subrenal capsule assays. Cancer Res. 1984 Mar;44(3):1087–1090. [PubMed] [Google Scholar]
  4. Borel J. F., Meszaros J. Skin transplantation in mice and dogs. Effect of cyclosporin A and dihydrocyclosporin C. Transplantation. 1980 Feb;29(2):161–162. [PubMed] [Google Scholar]
  5. Dialynas D. P., Wilde D. B., Marrack P., Pierres A., Wall K. A., Havran W., Otten G., Loken M. R., Pierres M., Kappler J. Characterization of the murine antigenic determinant, designated L3T4a, recognized by monoclonal antibody GK1.5: expression of L3T4a by functional T cell clones appears to correlate primarily with class II MHC antigen-reactivity. Immunol Rev. 1983;74:29–56. doi: 10.1111/j.1600-065x.1983.tb01083.x. [DOI] [PubMed] [Google Scholar]
  6. Eccles S. A., Heckford S. E., Alexander P. Effect of cyclosporin A on the growth and spontaneous metastasis of syngeneic animal tumours. Br J Cancer. 1980 Aug;42(2):252–259. doi: 10.1038/bjc.1980.224. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Griffin T. W., Bogden A. E., Reich S. D., Antonelli D., Hunter R. E., Ward A., Yu D. T., Greene H. L., Costanza M. E. Initial clinical trials of the subrenal capsule assay as a predictor of tumor response to chemotherapy. Cancer. 1983 Dec 15;52(12):2185–2192. doi: 10.1002/1097-0142(19831215)52:12<2185::aid-cncr2820521202>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  8. Hamburger A. W., Salmon S. E. Primary bioassay of human tumor stem cells. Science. 1977 Jul 29;197(4302):461–463. doi: 10.1126/science.560061. [DOI] [PubMed] [Google Scholar]
  9. Introna M., Allavena P., Spreafico F., Mantovani A. Inhibition of human natural killer activity by cyclosporin A. Transplantation. 1981 Feb;31(2):113–116. doi: 10.1097/00007890-198102000-00004. [DOI] [PubMed] [Google Scholar]
  10. Levi F. A., Blum J. P., Lemaigre G., Bourut C., Reinberg A., Mathé G. A four-day subrenal capsule assay for testing the effectiveness of anticancer drugs against human tumors. Cancer Res. 1984 Jun;44(6):2660–2667. [PubMed] [Google Scholar]
  11. Selby P., Buick R. N., Tannock I. A critical appraisal of the "human tumor stem-cell assay". N Engl J Med. 1983 Jan 20;308(3):129–134. doi: 10.1056/NEJM198301203080304. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES